Piramal Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Piramal Pharma Ltd reported a 28.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.1%.
• Its expenses for the quarter were up by 15.4% QoQ and 2.1% YoY.
• The net profit decreased 93.5% QoQ and decreased 105.7% YoY.
• The earnings per share (EPS) of Piramal Pharma Ltd declined at 0.07 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Piramal Pharma Ltd is a leading pharmaceutical company engaged in the manufacturing and marketing of a broad range of pharmaceutical products. The company operates primarily in the healthcare sector, offering services and products that include generic pharmaceuticals, over-the-counter (OTC) products, and specialty drugs. Piramal Pharma is known for its comprehensive portfolio aimed at addressing various therapeutic areas. As of the latest updates, there have been no major developments publicly announced that significantly alter the company's strategic direction or operations. The company's focus remains on leveraging its extensive market reach and diversified product offerings to maintain its competitive position in the pharmaceutical industry.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Piramal Pharma Ltd reported a total income of ₹2,797.83 crores. This represents a significant quarter-over-quarter (QoQ) increase of 28.2% compared to the previous quarter (Q3FY26), where the total income was ₹2,183.11 crores. Year-over-year (YoY) comparison with the same quarter of the previous fiscal year (Q4FY25) shows a marginal increase of 0.1%, where the total income stood at ₹2,796.10 crores. This suggests a stable revenue performance over the year, with a notable uptick in the most recent quarter.

Profitability

The company's profitability metrics for Q4FY26 indicate a challenging period. Profit Before Tax (PBT) was reported at ₹29.43 crores, reflecting a significant improvement from the negative PBT of ₹-104.12 crores in Q3FY26. However, when compared to Q4FY25, where PBT was ₹256.58 crores, there is a marked decline of 88.5% YoY. The tax expense for Q4FY26 was ₹51.83 crores, up 22.4% QoQ from ₹42.33 crores in Q3FY26, but down 56.6% YoY from ₹119.30 crores in Q4FY25. Consequently, the Profit After Tax (PAT) for Q4FY26 was a loss of ₹8.82 crores, albeit a reduction in loss compared to ₹-136.19 crores in the previous quarter. This is a stark contrast to the profit of ₹153.50 crores recorded in Q4FY25.

Operating Metrics

In terms of operating metrics, the company reported an Earnings Per Share (EPS) of ₹-0.07 for Q4FY26, showing an improvement from the previous quarter’s EPS of ₹-1.03. However, this is a decline from the EPS of ₹1.16 recorded in Q4FY25. The YoY change in EPS stands at -106.0%, indicating a significant reduction in earnings per share over the year. The QoQ change reflects a 93.2% improvement. These metrics highlight fluctuations in operational efficiency and profitability on a per-share basis. The financial data presented does not include specific information on liquidity or leverage ratios such as the current ratio or debt-to-equity ratio, which are also crucial for a comprehensive assessment of the company's financial health.